新生血管性AMD抗VEGF治疗中黄斑萎缩的4年MANEX研究
结果显示两种方案在MA发生率及进展速率上无显著差异,但T&E组注射次数更多且视力结局更好。
要点
- T&E与PRN方案在4年内对新发MA风险及已有MA进展均无显著影响(P=0.692)。
- 基线无MA眼4年新发MA比例:T&E组27%(34/124),PRN组25%(20/81)。
- 基线有MA眼MA面积平方根进展速率两组均为0.4 mm/年(T&E 0.4±0.2,PRN 0.4±0.1,P=0.23)。
核心结论
- 4年随访中,抗VEGF治疗方案的种类及注射频率不影响nAMD眼MA的发生率或进展。
- T&E方案注射次数更多,视力结局优于PRN方案。
研究设计与样本
- T&E组163例,PRN组101例,均接受抗VEGF治疗至少4年并每年行FAF和OCT检查。
- 两名设盲评分者独立勾画MA面积并计算增长率,新发MA采用比例风险比评估。
主要发现
- 基线MA患病率:T&E组24%,PRN组20%(P=0.45)。
- 第4年基线无MA眼新发MA:T&E组27%(34/124),PRN组25%(20/81)。
- 基线有MA眼MA面积平方根进展速率:T&E组0.4±0.2 mm/年,PRN组0.4±0.1 mm/年(P=0.23)。
- 多因素分析显示较高年龄、较差基线视力及视网膜血管瘤样增生与MA进展风险更高相关(P=0.03)。
- 回归分析显示T&E与PRN方案与4年新发MA风险或已有MA进展均无关联(P=0.692)。
临床怎么用
- 选择T&E或PRN方案时,MA发生与进展风险不作为决策依据。
- T&E方案注射次数更多但视力结局更好,需综合评估治疗负担与获益。
局限性
- 回顾性研究设计可能引入选择偏倚。
- 样本来自真实世界设置,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the incidence and progression of macular atrophy (MA) in eyes with neovascular age-related macular degeneration (nAMD) treated with anti-vascular endothelial growth factor (VEGF) agents using either a treat-and-extend (T&E) or a pro re nata (PRN) regimen over 4 years in a real-world setting. DESIGN: Four-year, multicenter, retrospective comparative study. PARTICIPANTS: Two hundred sixty-four patients with treatment-naive nAMD. METHODS: Consecutive patients with nAMD received anti-VEGF therapy according to a T&E (n = 163) or PRN (n = 101) regimen. Eyes were included if they had received anti-VEGF injections for a period of at least 4 years and had undergone annual fundus autofluorescence (FAF) and OCT imaging using Heidelberg Spectralis. Two masked graders independently delineated areas of MA from serial FAF images using Heidelberg region finder software, and growth rates were calculated. Incident MA was assessed using proportional hazard ratios. MAIN OUTCOMES MEASURES: Macular atrophy incidence and progression over 4 years, association between treatment strategies, and number of injections. RESULTS: At baseline, MA was present in 24% and 20% of study eyes in T&E and PRN groups, respectively (P = 0.45). At year 4, 27% (34/124) and 25% (20/81) of eyes without baseline MA showed detectable MA in the T&E and PRN groups, respectively. In those with MA at baseline, the mean square root area of MA progressed by a rate of 0.4 ± 0.2 mm/year and 0.4 ± 0.1 mm/year in the T&E and PRN groups, respectively (P = 0.23). Multivariate analysis for baseline predictors of MA growth demonstrated that older age, poorer baseline visual acuity, and presence of retinal angiomatous proliferation had a higher risk of greater MA progression (P = 0.03). Regression analysis demonstrated no association between T&E and PRN treatment strategies with the risk of new MA developing during the 4 years of follow-up or the progression of pre-existing MA at year 4 (P = 0.692). CONCLUSIONS: Over 4 years, neither incidence nor progression of MA in eyes with nAMD treated with anti-VEGF injections was influenced by the treatment regimen and injection frequency. Eyes treated with a T&E regimen received more injections and achieved better visual outcomes compared with those treated with a PRN approach.
引用
- Spooner KL, Fraser-Bell S, Cozzi M, et al. Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study. Ophthalmology. 2020. PMID: 32544561. doi:10.1016/j.ophtha.2020.06.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。